TD Asset Management Inc Has $2.88 Million Stock Position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

TD Asset Management Inc lifted its holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTLFree Report) by 5.2% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 190,168 shares of the company’s stock after acquiring an additional 9,400 shares during the period. TD Asset Management Inc owned approximately 0.27% of Zentalis Pharmaceuticals worth $2,881,000 as of its most recent filing with the SEC.

Other hedge funds have also bought and sold shares of the company. Exchange Traded Concepts LLC grew its holdings in shares of Zentalis Pharmaceuticals by 34.0% during the 4th quarter. Exchange Traded Concepts LLC now owns 5,989 shares of the company’s stock worth $91,000 after purchasing an additional 1,519 shares in the last quarter. Arizona State Retirement System lifted its position in Zentalis Pharmaceuticals by 20.2% during the third quarter. Arizona State Retirement System now owns 14,046 shares of the company’s stock worth $282,000 after purchasing an additional 2,363 shares during the period. Quest Partners LLC acquired a new stake in Zentalis Pharmaceuticals during the fourth quarter worth about $38,000. State Board of Administration of Florida Retirement System increased its holdings in Zentalis Pharmaceuticals by 19.1% in the 3rd quarter. State Board of Administration of Florida Retirement System now owns 16,619 shares of the company’s stock valued at $333,000 after buying an additional 2,670 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its position in shares of Zentalis Pharmaceuticals by 0.9% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 445,823 shares of the company’s stock valued at $6,754,000 after buying an additional 3,759 shares in the last quarter.

Analyst Ratings Changes

A number of research analysts recently issued reports on the stock. HC Wainwright decreased their price objective on shares of Zentalis Pharmaceuticals from $46.00 to $40.00 and set a “buy” rating on the stock in a research note on Wednesday, May 8th. Stifel Nicolaus dropped their price objective on Zentalis Pharmaceuticals from $36.00 to $32.00 and set a “buy” rating for the company in a research report on Wednesday, May 8th. Finally, Wedbush lifted their target price on Zentalis Pharmaceuticals from $12.00 to $15.00 and gave the company a “neutral” rating in a research report on Wednesday, February 28th. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, Zentalis Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $31.67.

View Our Latest Research Report on Zentalis Pharmaceuticals

Insider Activity

In related news, CFO Cam Gallagher sold 9,597 shares of the business’s stock in a transaction on Friday, May 31st. The shares were sold at an average price of $11.98, for a total value of $114,972.06. Following the sale, the chief financial officer now owns 633,680 shares of the company’s stock, valued at $7,591,486.40. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other news, insider Diana Hausman sold 3,356 shares of the stock in a transaction on Thursday, May 9th. The shares were sold at an average price of $12.62, for a total transaction of $42,352.72. Following the completion of the sale, the insider now directly owns 373,876 shares in the company, valued at $4,718,315.12. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CFO Cam Gallagher sold 9,597 shares of the business’s stock in a transaction on Friday, May 31st. The shares were sold at an average price of $11.98, for a total transaction of $114,972.06. Following the completion of the transaction, the chief financial officer now owns 633,680 shares in the company, valued at approximately $7,591,486.40. The disclosure for this sale can be found here. Insiders own 6.10% of the company’s stock.

Zentalis Pharmaceuticals Stock Down 4.2 %

Shares of ZNTL stock opened at $10.62 on Friday. The firm has a market capitalization of $754.34 million, a P/E ratio of -3.19 and a beta of 1.83. Zentalis Pharmaceuticals, Inc. has a twelve month low of $9.56 and a twelve month high of $30.53. The stock’s fifty day simple moving average is $12.55 and its 200 day simple moving average is $13.15.

Zentalis Pharmaceuticals (NASDAQ:ZNTLGet Free Report) last issued its quarterly earnings data on Tuesday, May 7th. The company reported $0.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.77) by $0.91. The business had revenue of $40.56 million during the quarter, compared to the consensus estimate of $35.00 million. During the same quarter last year, the business earned ($1.07) EPS. As a group, equities research analysts expect that Zentalis Pharmaceuticals, Inc. will post -2.72 EPS for the current fiscal year.

Zentalis Pharmaceuticals Company Profile

(Free Report)

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.

Featured Stories

Institutional Ownership by Quarter for Zentalis Pharmaceuticals (NASDAQ:ZNTL)

Receive News & Ratings for Zentalis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zentalis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.